Abiopharma

AKTIS ONCOLOGY, INC. (AKTS) Announces Clinical Trial Update AKTIS ONCOLOGY, INC. (AKTS) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: point, populations
• Collaboration: Oncology, Inc.
  • targeting B7-H3 expressing tumors, including prostate, lung and other solid tumors. Aktis has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline. For more information, please visit www.aktisoncology.com. Forward-looking statements This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933
  • targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second pipeline program, AKY-2519